Do analysts recommend CPHI or GNLX?

Genelux has a consensus target price of $18.00, indicating a potential upside of 516.44%. Given Genelux's stronger consensus rating and higher possible upside, analysts clearly believe Genelux is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Genelux 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is CPHI or GNLX more profitable?

Genelux has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets China Pharma -85.56% -63.93% -31.42% Genelux N/A -174.55% -123.65%

Do analysts recommend CGTX or CPHI?

Cognition Therapeutics currently has a consensus price target of $3.33, indicating a potential upside of 102.02%. Given Cognition Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cognition Therapeutics is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cognition Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor CGTX or CPHI?

In the previous week, Cognition Therapeutics and Cognition Therapeutics both had 3 articles in the media. China Pharma's average media sentiment score of 0.19 beat Cognition Therapeutics' score of 0.00 indicating that China Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral China Pharma 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer SPRO or CPHI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor SPRO or CPHI?

In the previous week, Spero Therapeutics had 1 more articles in the media than China Pharma. MarketBeat recorded 4 mentions for Spero Therapeutics and 3 mentions for China Pharma. Spero Therapeutics' average media sentiment score of 0.56 beat China Pharma's score of 0.19 indicating that Spero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spero Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive China Pharma 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CPHI or CRDL?

Cardiol Therapeutics has a consensus price target of $8.50, indicating a potential upside of 709.52%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cardiol Therapeutics is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cardiol Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Does the media refer more to CPHI or CRDL?

In the previous week, China Pharma had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 3 mentions for China Pharma and 2 mentions for Cardiol Therapeutics. China Pharma's average media sentiment score of 0.19 beat Cardiol Therapeutics' score of 0.00 indicating that China Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China Pharma 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardiol Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CPHI or MENS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, CPHI or MENS?

China Pharma has higher revenue and earnings than Jyong Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio China Pharma $3.99M 7.06 -$3.08M -$0.55 N/A Jyong Biotech N/A N/A -$4.67M N/A N/A

China Pharma (CPHI) Competitors

$0.70 -0.04 (-4.86%)

Closing price 06/23/2026 03:52 PM Eastern

Extended Trading

$0.72 +0.02 (+3.01%)

As of 06/23/2026 07:43 PM Eastern

Compare

CPHI vs. GNLX, CGTX, SPRO, CRDL, and MENS

Should you buy China Pharma stock or one of its competitors? MarketBeat compares China Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with China Pharma include Genelux (GNLX), Cognition Therapeutics (CGTX), Spero Therapeutics (SPRO), Cardiol Therapeutics (CRDL), and Jyong Biotech (MENS). These companies are all part of the "pharmaceutical products" industry.

How does China Pharma compare to Genelux?

China Pharma (NYSE:CPHI) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

In the previous week, China Pharma had 3 more articles in the media than Genelux. MarketBeat recorded 3 mentions for China Pharma and 0 mentions for Genelux. China Pharma's average media sentiment score of 0.19 beat Genelux's score of 0.00 indicating that China Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
China Pharma	Neutral
Genelux	Neutral

37.3% of Genelux shares are held by institutional investors. 6.4% of China Pharma shares are held by company insiders. Comparatively, 7.5% of Genelux shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

China Pharma has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.99M	7.06	-$3.08M	-$0.55	N/A
Genelux	$10K	13,093.28	-$32.15M	-$0.85	N/A

Genelux has a consensus target price of $18.00, indicating a potential upside of 516.44%. Given Genelux's stronger consensus rating and higher possible upside, analysts clearly believe Genelux is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

China Pharma has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, Genelux has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

Genelux has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Genelux	N/A	-174.55%	-123.65%

Summary

China Pharma beats Genelux on 9 of the 16 factors compared between the two stocks.

How does China Pharma compare to Cognition Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and China Pharma (NYSE:CPHI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

In the previous week, Cognition Therapeutics and Cognition Therapeutics both had 3 articles in the media. China Pharma's average media sentiment score of 0.19 beat Cognition Therapeutics' score of 0.00 indicating that China Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
China Pharma	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

43.4% of Cognition Therapeutics shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by company insiders. Comparatively, 6.4% of China Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

China Pharma has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A
China Pharma	$3.99M	7.06	-$3.08M	-$0.55	N/A

Cognition Therapeutics has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market. Comparatively, China Pharma has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

Cognition Therapeutics currently has a consensus price target of $3.33, indicating a potential upside of 102.02%. Given Cognition Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cognition Therapeutics is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Cognition Therapeutics has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-72.68%	-53.07%
China Pharma	-85.56%	-63.93%	-31.42%

Summary

Cognition Therapeutics beats China Pharma on 8 of the 14 factors compared between the two stocks.

How does China Pharma compare to Spero Therapeutics?

Spero Therapeutics (NASDAQ:SPRO) and China Pharma (NYSE:CPHI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

25.6% of Spero Therapeutics shares are held by institutional investors. 2.9% of Spero Therapeutics shares are held by insiders. Comparatively, 6.4% of China Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Spero Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market. Comparatively, China Pharma has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

Spero Therapeutics has a net margin of 24.90% compared to China Pharma's net margin of -85.56%. Spero Therapeutics' return on equity of 35.58% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	35.58%	24.95%
China Pharma	-85.56%	-63.93%	-31.42%

In the previous week, Spero Therapeutics had 1 more articles in the media than China Pharma. MarketBeat recorded 4 mentions for Spero Therapeutics and 3 mentions for China Pharma. Spero Therapeutics' average media sentiment score of 0.56 beat China Pharma's score of 0.19 indicating that Spero Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spero Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
China Pharma	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spero Therapeutics has higher revenue and earnings than China Pharma. China Pharma is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$66.80M	1.86	$8.57M	$0.24	8.96
China Pharma	$3.99M	7.06	-$3.08M	-$0.55	N/A

Summary

Spero Therapeutics beats China Pharma on 12 of the 14 factors compared between the two stocks.

How does China Pharma compare to Cardiol Therapeutics?

China Pharma (NYSE:CPHI) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

China Pharma has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.99M	7.06	-$3.08M	-$0.55	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A

12.5% of Cardiol Therapeutics shares are owned by institutional investors. 6.4% of China Pharma shares are owned by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

China Pharma has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market.

In the previous week, China Pharma had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 3 mentions for China Pharma and 2 mentions for Cardiol Therapeutics. China Pharma's average media sentiment score of 0.19 beat Cardiol Therapeutics' score of 0.00 indicating that China Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
China Pharma	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cardiol Therapeutics has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Cardiol Therapeutics	N/A	-229.43%	-165.60%

Cardiol Therapeutics has a consensus price target of $8.50, indicating a potential upside of 709.52%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cardiol Therapeutics is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

China Pharma beats Cardiol Therapeutics on 9 of the 15 factors compared between the two stocks.

How does China Pharma compare to Jyong Biotech?

China Pharma (NYSE:CPHI) and Jyong Biotech (NASDAQ:MENS) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

China Pharma has higher revenue and earnings than Jyong Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.99M	7.06	-$3.08M	-$0.55	N/A
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A

In the previous week, China Pharma had 3 more articles in the media than Jyong Biotech. MarketBeat recorded 3 mentions for China Pharma and 0 mentions for Jyong Biotech. China Pharma's average media sentiment score of 0.19 beat Jyong Biotech's score of 0.00 indicating that China Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
China Pharma	Neutral
Jyong Biotech	Neutral

Jyong Biotech has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. Jyong Biotech's return on equity of 0.00% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Jyong Biotech	N/A	N/A	N/A

Summary

China Pharma and Jyong Biotech tied by winning 4 of the 8 factors compared between the two stocks.

Get China Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPHI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CPHI vs. The Competition

Export

Metric	China Pharma	Pharmaceutical Industry	Medical Sector	NYSE Exchange
Market Cap	$29.61M	$929.60M	$6.44B	$23.25B
Dividend Yield	N/A	4.84%	2.69%	4.06%
P/E Ratio	-1.26	1.45	24.66	31.08
Price / Sales	7.06	113.99	531.91	105.72
Price / Cash	N/A	20.06	44.82	24.45
Price / Book	0.99	7.75	10.81	4.64
Net Income	-$3.08M	-$3.91M	$3.56B	$1.07B
7 Day Performance	-13.54%	1.63%	0.93%	0.13%
1 Month Performance	-8.50%	2.02%	0.35%	0.15%
1 Year Performance	-59.59%	52.11%	29.69%	23.17%

China Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CPHI China Pharma	N/A	$0.70 -4.9%	N/A	-58.6%	$29.61M	$3.99M	N/A	250	News Coverage
GNLX Genelux	1.4324 of 5 stars	$2.96 +3.9%	$18.00 +508.1%	+5.4%	$127.79M	$10K	N/A	10
CGTX Cognition Therapeutics	3.786 of 5 stars	$1.45 +2.1%	$3.33 +129.9%	+535.8%	$127.09M	N/A	N/A	20	News Coverage Analyst Forecast Gap Down
SPRO Spero Therapeutics	1.4161 of 5 stars	$2.28 +8.1%	N/A	-26.6%	$122.17M	$66.80M	9.50	150	Gap Up High Trading Volume
CRDL Cardiol Therapeutics	1.7849 of 5 stars	$1.06 flat	$8.50 +701.9%	-18.0%	$122.16M	N/A	N/A	20	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CPHI) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

China Pharma (CPHI) Competitors

CPHI vs. GNLX, CGTX, SPRO, CRDL, and MENS

How does China Pharma compare to Genelux?

Summary

How does China Pharma compare to Cognition Therapeutics?

Summary

How does China Pharma compare to Spero Therapeutics?

Summary

How does China Pharma compare to Cardiol Therapeutics?

Summary

How does China Pharma compare to Jyong Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPHI vs. The Competition

China Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

China Pharma (CPHI) Competitors

CPHI vs. GNLX, CGTX, SPRO, CRDL, and MENS

How does China Pharma compare to Genelux?

Does the media prefer CPHI or GNLX?

Do insiders and institutionals have more ownership in CPHI or GNLX?

Which has better valuation & earnings, CPHI or GNLX?

Do analysts recommend CPHI or GNLX?

Which has more risk & volatility, CPHI or GNLX?

Is CPHI or GNLX more profitable?

Summary

How does China Pharma compare to Cognition Therapeutics?

Does the media favor CGTX or CPHI?

Do insiders & institutionals believe in CGTX or CPHI?

Which has stronger valuation & earnings, CGTX or CPHI?

Which has more risk and volatility, CGTX or CPHI?

Do analysts recommend CGTX or CPHI?

Is CGTX or CPHI more profitable?

Summary

How does China Pharma compare to Spero Therapeutics?

Do analysts prefer SPRO or CPHI?

Do insiders and institutionals believe in SPRO or CPHI?

Which has more risk and volatility, SPRO or CPHI?

Is SPRO or CPHI more profitable?

Does the media favor SPRO or CPHI?

Which has stronger earnings & valuation, SPRO or CPHI?

Summary

How does China Pharma compare to Cardiol Therapeutics?

Which has higher valuation and earnings, CPHI or CRDL?

Do institutionals & insiders believe in CPHI or CRDL?

Which has more volatility & risk, CPHI or CRDL?

Does the media refer more to CPHI or CRDL?

Is CPHI or CRDL more profitable?

Do analysts recommend CPHI or CRDL?

Summary

How does China Pharma compare to Jyong Biotech?

Do analysts rate CPHI or MENS?

Which has higher earnings and valuation, CPHI or MENS?

Does the media favor CPHI or MENS?

Is CPHI or MENS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPHI vs. The Competition

China Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools